Vogt A. Lipoprotein(a)-antisense therapy. Clin Res Cardiol Suppl. 2019;: pubmed publisher
..Tolerability and safety were confirmed, whereby injection site reactions were the most common side effects. This raises hope that the planned phase 3 trial will reproduce these findings and show a reduction of cardiovascular events. ..
Vogt A. [PCSK9 inhibitors : Current clinical relevance]. Internist (Berl). 2017;58:196-201 pubmed publisher
..The body of evidence is rapidly increasing thereby facilitating the decision making when PCSK9 inhibitors could be used. The PCSK9 inhibitors will considerably improve the options for optimal treatment of high-risk patients. ..
Vogt A. Hyperlipoproteinaemia(a) - apheresis and emerging therapies. Clin Res Cardiol Suppl. 2017;12:12-17 pubmed publisher
..Currently LA is the standard of care as a last resort treatment in high-risk patients with elevated Lp(a) and severe CVD despite optimal control of all other cardiovascular risk factors. ..
Vogt A. Lipoprotein(a)-apheresis in the light of new drug developments. Atheroscler Suppl. 2017;30:38-43 pubmed publisher
..8%) in healthy volunteers. Despite the lack of prospective randomised trials apheresis these days remains the standard of care in patients with elevated Lp(a) and severe CVD. ..